Lenalidomid Ethypharm (Lenalidomide)

Lenalidomide binds to cereblon, a component of the CRL4‑CRBN E3 ubiquitin ligase complex. This binding changes the complex’s activity, leading to the degradation of transcription factors Ikaros and Aiolos. The resulting anti‑angiogenic, immunomodulatory, and anti‑proliferative actions help suppress the growth of malignant blood cells.

The specific dose of Lenalidomid Ethypharm is determined by the prescribing clinician based on the patient’s diagnosis, disease stage, renal and hepatic function, and other individual factors. Only a qualified healthcare professional can set the appropriate dosing regimen.

Lenalidomid Ethypharm is classified as potentially teratogenic, and its safety in pregnancy has not been established. Women of childbearing potential should use effective contraception during treatment and for a defined period after the last dose. Breastfeeding is not recommended while taking this medication.

To place an order, submit an enquiry on the product page at gnhindia.com with the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide, and will request verification of trade or institutional credentials. After confirmation, the team provides pricing, availability, shipping details and any necessary import documentation.

Lenalidomide belongs to the immunomodulatory drug class, offering a distinct mechanism compared with proteasome inhibitors or monoclonal antibodies. It provides oral administration, which can be advantageous for outpatient care, and has demonstrated efficacy in improving progression‑free survival when used alone or in combination with other agents.

Lenalidomid Ethypharm should be stored at room temperature, below 25 °C, in its original packaging. The container should be kept closed to protect the tablets from moisture and light, ensuring the product maintains its stability throughout its shelf life.

The medication is taken orally, usually with or without food, as directed by the prescribing physician. Patients should swallow the tablet whole with a glass of water and follow any specific timing instructions provided by their healthcare provider.

Serious risks include venous thromboembolism, severe cutaneous reactions such as Stevens‑Johnson syndrome, secondary primary malignancies, hepatic failure, and interstitial lung disease. Patients should be monitored closely for signs of these events, and any concerning symptoms should prompt immediate medical evaluation.

Lenalidomid Ethypharm is contraindicated in patients who are pregnant, have known hypersensitivity to lenalidomide or any excipients, or have uncontrolled severe infections. Caution is also advised for individuals with significant renal or hepatic impairment, and those with a high baseline risk of thromboembolic events.